2104 related articles for article (PubMed ID: 16955068)
41. Isoform-specific histone deacetylase inhibitors: the next step?
Balasubramanian S; Verner E; Buggy JJ
Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
43. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
44. Histone deacetylase inhibitors: multifunctional anticancer agents.
Liu T; Kuljaca S; Tee A; Marshall GM
Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
[TBL] [Abstract][Full Text] [Related]
45. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
46. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
47. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
48. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
50. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
51. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
53. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation.
Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM
Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
55. Regulation of histone deacetylase activities.
Sengupta N; Seto E
J Cell Biochem; 2004 Sep; 93(1):57-67. PubMed ID: 15352162
[TBL] [Abstract][Full Text] [Related]
56. [Histone deacetylases: a new class of efficient anti-tumor drugs].
Mottet D; Castronovo V
Med Sci (Paris); 2008; 24(8-9):742-6. PubMed ID: 18789222
[TBL] [Abstract][Full Text] [Related]
57. HDACi--targets beyond chromatin.
Buchwald M; Krämer OH; Heinzel T
Cancer Lett; 2009 Aug; 280(2):160-7. PubMed ID: 19342155
[TBL] [Abstract][Full Text] [Related]
58. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?
Grayson DR; Kundakovic M; Sharma RP
Mol Pharmacol; 2010 Feb; 77(2):126-35. PubMed ID: 19917878
[TBL] [Abstract][Full Text] [Related]
59. Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.
Curtin ML
Curr Opin Drug Discov Devel; 2004 Nov; 7(6):848-68. PubMed ID: 15595445
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
Garcia-Manero G; Issa JP
Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]